cagrilintide semaglutide phase 2 weight loss Efficacy and safety of co-administered once-weekly 2·4 mg with once-weekly 2·4 mg in type diabetes: a multicentre, randomised, double-blind, active-controlled, 2 trial In the REDEFINE 2 phase

In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Dual Therapy CagriSema Promising for Weight and Glycaemic Control EMJ CagriSema: a novel dual pathway approach to target obesity and its complications CagriSema in Adults With or Without Diabetes REDEFINE 1 & 2 Cagrilintide 2.4 mg + Semaglutide 2.4 mg once weekly 20.4% weight loss (non diabetic) & 13.7% (T2D)

SKU: 58173805040 · From cantondelareina.com.ar